<DOC>
	<DOCNO>NCT02513329</DOCNO>
	<brief_summary>Vasomotor symptom ( VMS ) affect 65 % breast cancer survivor negatively impact quality life . The investigator aim evaluate benefit SGB symptomatic woman breast cancer anti-estrogens seek relief moderate severe VMS adversely affect health wellbeing . Women breast cancer Tamoxifen , aromatase inhibitor ( AIs ) Selective Estrogen Receptor Modulators ( SERMS ) moderate severe VMS enrol participant study .</brief_summary>
	<brief_title>Stellate Ganglion Block ( SGB ) For Women Breast Cancer</brief_title>
	<detailed_description>Hypotheses : The frequency intensity subjective objective VMS significantly low woman randomize active SGB compare sham control . Mood , memory , cognition , sleep , quality life improve treatment group compare sham-control group . Specific Goals Objectives : Goal 1 : To determine effect stellate ganglion blockade ( SGB ) reduce subjective objective VMS woman breast cancer tamoxifen , AIs , SERMs Goal 2 : To evaluate effect SGB mood , memory , cognition , sleep quality life woman breast cancer tamoxifen , AIs , SERMs . We aim conduct randomize , single-site , sham-control clinical trial SGB VMS 30 woman breast cancer anti-estrogen therapy ( 15 per group ) . The primary entry criterion 28 moderate severe hot flash per week . VMS measure self-report write daily dairy 6-month period . Secondary outcome include change mood , sleep , quality life , objective hot flash measure ambulatory monitoring ( skin-conductance temperature monitoring ) 24 hour baseline , three month six month . Memory performance neurocognitive test do baseline 3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Estrogen Antagonists</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1. age 30 70 year 2 . 28 report moderatetovery severe hot flash per week 3. minimum two week VMS diary record prior SGB 4. current use tamoxifen , aromatase inhibitor , SERMs breast cancer indication last six month 5. willingness undergo fluoroscopyguided SGB sham treatment . 6 . Approval healthcare provider ≥ 21 depression ≥15 anxiety Depression Anxiety Stress Scale ( DASS ) 7 . Stable use Selective Serotonin Reuptake Inhibitors ( SSRIs ) , Selective Norepinephrine Reuptake Inhibitors ( SNRIs ) applicable 1. condition preclude SGB sham intervention ( e.g. , anatomic abnormality anterior neck cervical spine ; goiter , cardiac/pulmonary compromise ; acute illness/infection ; coagulopathy bleeding disorder ; allergic reactions/contraindications local anesthetic contrast dye ) ; 2. use treatment past two month affect VMS ( e.g. , use oral transdermal Hormone Treatment ( HT ) contraceptives , SERMS , 3. condition disorder affect performance cognitive test ( e.g. , dementia/mild cognitive impairment ; stroke ; traumatic brain injury ; alcohol/substance use ; inability write , speak , read English , English second language 4 . MiniMental State Exam ( MMSE ) ≥ 28 5. condition affect sleep quality ( e.g. , use sleep agent ; shift work ; etc . )</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Anti-estrogens</keyword>
	<keyword>Hot Flushes</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Hot Flashes</keyword>
</DOC>